Metastatic Non-Small Cell Lung Cancer 2024 UPDATE

Dr. Jennifer Marks, a Thoracic Oncologist at the Dana-Farber Cancer Institute, dives deep into metastatic non-small cell lung cancer. She highlights the rapidly evolving systemic therapy options, including traditional chemotherapy and cutting-edge immunotherapies. The discussion emphasizes the critical role of PD-L1 testing in treatment decisions and the impact of key mutations like EGFR and HER2 on targeted therapies. Listeners learn about the latest FDA approvals and strategies for managing treatment-related side effects, showcasing the dynamic landscape of lung cancer treatment.